Korea Business News Agency - NSP NEWS AGENCY.

(Seoul=NSP NEWS) = Hanmi Pharm announced two findings from research on LAPSTriple agonist (LAPSTriple) that the company was developing as an innovative new drug for non-alcoholic steatohepatitis (NASH).

The tests evaluated LAPSTriple’s direct improvement of liver fibrosis, a key indicator in NASH treatment, and the result was presented at the European Association for the Study of the Liver (EASL) in Vienna, Austria, on June 21 to 24 (local time).

In the event, the Korean pharmaceutical company showed that LAPSTriple has a direct improvement in liver inflammation and fibrosis through replicable test results from various animal models of liver fibrosis without fatty liver.

Also, it proved how LAPSTriple sets it apart from other incretin analogues (GLP-1, GLP-1·GIP) in liver fibrosis improvement efficacy.

A Hanmi Pharma official said, “LAPSTriple agonist directly acts on the liver and better improves liver fibrosis than other substances” and added, “We will focus on our R&D capabilities in developing LAPSTriple to let it become a gamechanger in the NASH treatment where a formation of 30 trillion won worth of global market is estimated."

By Hyun-jin Kim(kimhj30310@nspna.com) and Da-eun Kim(ekdms8381@nspna.com)

ⓒNSP News Agency·NSP TV. All rights reserved.